25th Congress of the APSR
Assembly symposia
(scheduled as of 14 Nov 2021)- Assembly Symposium 1: Clinical Respiratory Medicine
Haemoptysis with radiological clinical correlation
Session summary: In clinical practice, haemoptysis is one of the most common respiratory chief complaints which physicians encountered in various clinical settings. Some cases might be urgent to diagnose and manage massive haemoptysis due to diffuse alveolar hemorrhage and bronchiectasis, accompanied by respiratory failure. In some Asian regions, patients suffer from persistent haemoptysis as the symptom associated with chronic respiratory infections. In this session, we would like to share information that enables appropriate medical care through understanding the pathophysiology and clinical radiological features of respiratory bleeding and haemoptysis related to lung disease.
Chairs: Dushantha Madegedara (National Hospital, Kandy, Sri Lanka)
Naozumi Hashimoto (Nagoya University, Japan)[Educational Lecture]
Indwelling pleural catheter management in malignant pleural effusion
Rajesh Thomas (Sir Charles Gairdner Hospital and University of Western Australia, Australia)[Symposium]
- Pathophysiological basis of Haemoptysis
Koji Sakamoto (Nagoya University, Japan) - How to investigate patients with Haemoptysis
Dushantha Madegedara (National Hospital, Kandy, Sri Lanka) - Radiological investigations in Haemoptysis
Bhavin Jankharia (Picture This, Mumbai, India)
- Pathophysiological basis of Haemoptysis
- Assembly Symposium 2: Cell and Molecular Biology
Hot topics in respiratory research
Chairs: Hidenori Kage (The University of Tokyo, Japan)
Takuji Suzuki (Chiba University, Japan)[Educational Lecture]
How do we use mice in medical research?
Akihisa Mitani (The University of Tokyo Hospital, Japan)[Symposium]
- Cell type- and region-specific mucin and CFTR expression in the airway
Kenichi Okuda (Cystic Fibrosis/Pulmonary Research and Treatment Center and University of North Carolina at Chapel Hill, USA) - Role of p300 in the cigarette smoke-induced impaired immune response in macrophages
Chul-Gyu Yoo (College of Medicine, Seoul National University, Republic of Korea) - Targeting Supernumerary Centrosomes to Combat Lung Cancer
Masanori Kawakami (The University of Tokyo, Japan)
- Cell type- and region-specific mucin and CFTR expression in the airway
- Assembly Symposium 3: Clinical Allergy & Immunology
Current Topics in Asthma
Session summary: The widespread use of ICS and ICS/LABA has significantly improved asthma control, and various biologics have been used for severe asthma, allowing many patients to benefit from them. However, the impact of COVID-19, which caused a pandemic that began in 2020, on asthma must also be considered. Under this backdrop and following educational lecture on severe asthma, three asthma topics will be covered in lectures: severe T2-high asthma (Prof. Pavord), COVID-19 (Prof. Jenkins) and ILC2 (Prof. Fukunaga) in this symposium. This symposium will surely be beneficial to the audience members involved in providing asthma treatments.
Chairs: Janet Rimmer (St Vincents Clinic, Australia)
Takashi Iwanaga (Kindai University Hospital, Japan)[Educational Lecture]
Difficult to treat and severe asthma in adults
Takashi Iwanaga (Kindai University Hospital, Japan)[Symposium]
- Severe T2-high asthma in the biologics era
Ian Pavord (University of Oxford, UK) - Asthma and covid-19 mortality
Christine Jenkins (The George Institute for Global Health, Australia) - ILC2 regulatory network and asthma
Koichi Fukunaga (Keio University School of Medicine, Japan)
- Severe T2-high asthma in the biologics era
- Assembly Symposium 4: Environmental & Occupational Health and Epidemiology
Emerging occupational and environmental interstitial lung diseases
Session summary: This symposium focusing on “Emerging occupational and environmental interstitial lung diseases”, starting with an Educational Lecture entitled “Air pollution and respiratory diseases” by Prof. Yatera to discuss broad aspects of occupational and environmental interstitial lung diseases, followed by the report entitled “Silicosis, a re-emerging occupational ILD” by Prof Yates. Then Prof. Myong will explain about very unique and critical situation occurred in the users of humidifier in detail entitled “Humidifier disinfectant related lung diseases”, and lastly, Prof. Morimoto will explain about “Recent advances in occupational and environmental ILD” including new harmful substances causing ILD in human.
Chairs: Woo Jin Kim (Kangwon National University, Republic of Korea)
Kazuhiro Yatera (University of Occupational and Environmental Health, Japan)[Educational Lecture]
Air pollution and respiratory diseases
Kazuhiro Yatera (University of Occupational and Environmental Health, Japan)[Symposium]
- Silicosis, a re-emerging occupational ILD
Deborah H Yates (University of NSW, Australia) - Humidifier disinfectant related lung diseases
Jun-Pyo Myong (Seoul St. Mary's Hospital,College of Medicine, the Catholic University of Korea, Republic of Korea) - Recent advances in occupational and environmental ILD
Yasuo Morimoto (University of Occupational and Environmental Health, Japan)
- Silicosis, a re-emerging occupational ILD
- Assembly Symposium 5: Respiratory Infections (non-tuberculous)
Novel approaches on treatment of respiratory infectious disease
Session summary: Although COVID-19 pandemic is ongoing, other respiratory infections also play important roles. In this symposium, we will discuss new treatment strategies for respiratory infectious disease. Dr Ku from Taiwan will talk management of critically ill patients with influenza as educational lecture. In symposium parts, Dr Sakagami from Japan will talk the topic of relationship between susceptibility factors of host and treatment of infectious disease. Dr Lee from USA will talk the topic of cell based the therapy. Dr Kido from Japan will talk the topic of novel vaccination for respiratory viral infection. We hope that the knowledge gained at this symposium will lead to further measures against respiratory infections including COVID-19.
Chairs: Chieh Liang Wu (Taichung Veterans General Hospital, Taiwan)
Masaki Fujita (Fukuoka University Hospital, Japan)[Educational Lecture]
Management of critically ill patients with influenza
Shih-Chi Ku (National Taiwan University Hospital, Taiwan)[Symposium]
- Possibility of treating infectious disease by intervention to host susceptibility factors
Takuro Sakagami (Kumamoto University, Japan) - Cell-based therapy on infectious disease-mechanism and efficacy
Jae Woo Lee (University of California, San Francisco, USA) - Development of trans-airway and oral vaccines against respiratory viral infections using effective mucosal adjuvant SF10 based on human pulmonary surfactant
Hiroshi Kido (Tokushima University, Institute of Advanced Medical Sciences, Japan)
- Possibility of treating infectious disease by intervention to host susceptibility factors
- Assembly Symposium 6: Tuberculosis
Artificial Intelligence in TB Diagnostics
Chairs: Charles Y. Yu (De La Salle Medical and Health Sciences Institute, Philippines)
Jennifer Ann M. Wi (Lyceum Northwestern FQ Duque College of Medicine, Philippines)[Educational Lecture]
Message to TB clinicians: Evidence and techniques for proper sampling to ensure bacteriological TB confirmation for the treatment based on drug susceptibility test results
Jin Takasaki (National Center for Global Health and Medicine, Japan)[Symposium]
- Should This be part of Screening?
Jacob H Creswell (Stop TB Partnership, Switzerland) - Role of X-ray for detection of TB
Ikushi Onozaki (Research Institute of Tuberculosis, Japan) - Innovations in X-Ray and Artificial Intelligence Computer-Aided Detection (CAD) Software for TB Response-expereience from the field and procurement availability
Zhi Zhen Qin (Stop TB Partnership / United Nations Office for Project Services, Switzerland)
- Should This be part of Screening?
- Assembly Symposium 7: Respiratory Neurobiology and Sleep
Alternative treatments for obstructive sleep apnea
Session summary: Continuous positive airway pressure (CPAP) therapy has been developed by Colin Sullivan in 1980, and has been recognized as the standard therapy for obstructive sleep apnea (OSAS) after decades of development and innovation. However, there are barriers for adherence to CPAP treatment. Barriers include psychological avoidance and practical problems such as difficulties in adjusting the mask and pressure from the mask. In addition, many patients choose not to travel with CPAP machine because it is bulky to carry. Therefore, there are needs to develop alternative therapies. Here, we invited two speakers: Prof. Makoto Sato will talk about nasal airway stent, and Prof. Danny Eckert will talk about pharmacological interventions for OSAS.
Chairs: Danny J. Eckert (College of Medicine and Public Health, Flinders University, Australia)
Yoshitaka Oku (Hyogo College of Medicine, Japan)[Educational Lecture]
Respiratory control during sleep – from bench to bedside
Yoshitaka Oku (Hyogo College of Medicine, Japan)[Symposium]
- Nasal airway stent
Makoto Satoh (University of Tsukuba, Moriya Keiyu Hospital, Japan) - Pharmacological interventions for obstructive sleep apnea
Danny J. Eckert (College of Medicine and Public Health, Flinders University, Australia)
- Nasal airway stent
- Assembly Symposium 8: Critical Care Medicine
Critical Illness in Cancer Patients
Session summary: Many conditions can be complicated in cancer patients. Infectious diseases and drug-induced organ damage are mentioned in the emergent disease state, but it is important to understand the response to their conditions firmly.In recent years, it is necessary to pay attention to the treatment of disorders caused by molecularly targeted drugs and immune checkpoint inhibitors, which are often used in cancer treatment, and the one under the spread of infectious diseases. In this symposium, these management will be summarized.
Chairs: Rex Chin-Wei Yung (IONIQ Sciences Inc, USA, Johns Hopkins University, USA (retired))
Akihiko Gemma (Nippon Medical School, Japan)[Educational Lecture]
Management and problem of oncologic emergency in advanced lung cancer
Kyoichi Kaira (Saitama Medical university, International Medical Center, Japan)v[Symposium]- Overview
Rex Chin-Wei Yung (IONIQ Sciences Inc, USA, Johns Hopkins University, USA (retired)) - Clinical Question 1: Clinical problems in the treatment for advanced lung cancer with interstitial pneumonia: focusing on the pulmonary toxicity of cytotoxic anticancer agents and immune checkpoint inhibitors
Motoyasu Kato (Juntendo University Graduate School of Medicine, Japan) - Clinical Question 2: Manifestation and management of toxicities of target therapy in cancer patients with critical illness
Jia-Yih Feng (Taipei Veterans General Hospital, Taiwan) - Summary
Akihiko Gemma (Nippon Medical School, Japan)
- Overview
- Assembly Symposium 9: Bronchoscopy and Interventional Techniques
Mediastinal staging – state of the art in the era of lung ablation
Session summary: Radial EBUS is effective in diagnosing the depth of lung cancer to the bronchial wall and for defining the biopsy site of peripheral lung lesions. On the other hand, Convex EBUS is an essential method for diagnosing hilar and mediastinal lesions and for determining the stage of lung cancer. In this session, Dr Nakajima and Dr Yasufuku, who has been involved in the development and promotion of convectional ultrasound bronchoscopy for many years, will give lectures. Dr Nakajima will give a review of EBUS in the educational lecture, and Dr Yasufuku will present the latest information on transbronchial ablation of lung cancer in the symposium. Accurate staging and genetic diagnosis are essential for the treatment of lung cancer. In this regard, Dr Tu will talk about the use of EBUS-TBNA and EUS-B-FNA, while Dr Oki will focus on techniques for obtaining good specimen and increasing diagnostic yield. Through this symposium, participants will be able to understand the basics of EBUS, get the latest information, and learn practical techniques for clinical use.
Chairs: Phan Nguyen (Royal Adelaide Hospital, Australia)
Fumihiro Asano (Gifu Prefectural General Medical Center, Japan)[Educational Lecture]
EBUS
Takahiro Nakajima (Dokkyo Medical University, Japan)[Symposium]
- Bronchoscopic lung cancer ablation – are we ready for prime time?
Kazuhiro Yasufuku (Toronto General Hospital, UHN, University of Tronto, Canada) - EBUS-TBNA and EUS-B-FNA: From staging to re-biopsy in Lung cancer
Chih-Yen Tu (China Medical University Hospital, Taiwan) - EBUS staging – how to improve reach and yield
Masahide Oki (National Hospital Organization Nagoya Medical Center, Japan)
- Bronchoscopic lung cancer ablation – are we ready for prime time?
- Assembly Symposium 10: Paediatric Lung Disease
Paediatric Respiratory Potpourri
Session summary: In Educational Lecture, we will discuss the pathogenesis, diagnosis and treatment of virus-induced asthma in preschool asthma, which causes airway epithelial damage and induces type 2 inflammation via the ILC2. In particular, we will review the evidence-based pathogenesis and exacerbation of asthma in infants with a focus on the RS virus. In the symposium, recent topics on respiratory diseases in children will be discussed. I will talk about the Respiratory Service for COVID-19 and a novel non-invasive respiratory therapy effective for sputum excretion using biphasic cuirass ventilation in paediatric respiratory diseases. As mentioned above, symposium 10 will be useful for tomorrow's practice, so please join us.
Chairs: Jessie de Bruyne (UM Specialist Centre, University of Malaysia Medical Centre, Malaysia)
Shigemi Yoshihara (Department of Pediatrics, Dokkyo Medical University, Japan)[Educational Lecture]
Viral infections and preschool asthma
Shigemi Yoshihara (Department of Pediatrics, Dokkyo Medical University, Japan)[Symposium]
- Running a Respiratory Service in the light of COVID
Teoh Oon Hoe (KK Women’s and Children’s Hospital, Singapore) - Respiratory therapy for children using Biphasic Cuirass Ventilation
Kuniyuki Okada (OKADA Kodomonomori Clinic, Saitama Medical University, Japan)
- Running a Respiratory Service in the light of COVID
- Assembly Symposium 11: Respiratory Structure and Function
Physiological assessment of airway by oscillometry
Chairs: Gregory G King (Royal North Shore Hospital, Australia)
Hajime Kurosawa (Tohoku University, Japan)[Educational Lecture]
Lung and chest wall mechanics
Troy J Cross (The University of Sydney, Australia)[Symposium]
- Overview and perspective
David A Kaminsky (University of Vermont Larner College of Medicine, USA) - Clinical application in asthma
Gregory G King (Royal North Shore Hospital, Australia) - Clinical application in COPD
Toshihiro Shirai (Shizuoka General Hospital, Japan)
- Overview and perspective
- Assembly Symposium 12: Interstitial Lung Disease
Beyond current treatment of IPF
Session summary: AS12 will be announced on the theme of the latest information on ILD. Drug development, which began with treatment to suppress the progression of IPF, has had a major impact not only on IPF but also on the management and treatment of ILD, or progressive fibrosing ILD (PF-ILD), which presents with progressive pathology other than IPF.
First, I would like to introduce the benefits of IPF antifibrotic drug treatments based on their historical background. Prof. Martin Kolb will discuss the possibility of IPF treatments with a new mechanism of action. Is the ultimate goal of treating pulmonary fibrosis to suppress the decrease in FVC due to fibrosis? This is one of the major issues of future study.
Dr Moo Suk Park will discuss the current status of IPF treatments. Prof. Takafumi Suda mentioned ILDs other than IPF, in which the progression of fibrosis determined the prognosis.
Chairs: Arata Azuma (Nippon Medical School, Japan)
Takafumi Suda (Hamamatsu University School of Medicine, Japan)[Educational Lecture]
Current anti-fibrotic treatment of IPF, real-world
Arata Azuma (Nippon Medical School, Japan)v[Symposium]- New pharmacologic agents for treatment of IPF
Martin Kolb (McMaster University, Canada) - Current treatment of IPF: Unsolved Issues and future directions
Moo Suk Park (Yonsei University College of Medicine, Severance Hospital, Republic of Korea) - Anti-fibrotic treatment of PF-ILD beyond IPF
Takafumi Suda (Hamamatsu University School of Medicine, Japan)
- New pharmacologic agents for treatment of IPF
- Assembly Symposium 13: COPD
Precision medicine in COPD
Chairs: Chin Kook Rhee (Seoul St. Mary's Hospital, The Catholic University of Korea, Republic of Korea)
Kazuto Matsunaga (Yamaguchi University, Japan)[Educational Lecture]
No more waiting for COPD patients
Kazuto Matsunaga (Yamaguchi University, Japan)[Symposium]
- Early and Pre-COPD
Bartolome Celli (Harvard Medical School, USA) - Identification of COPD exacerbation prone
Diahn-Warng Perng (Taipei Veterans General Hospital, Taipei, Taiwan) - Factors associated with clinical course of COPD
Masaru Suzuki (Hokkaido University, Japan)
- Early and Pre-COPD
- Assembly Symposium 14: Lung Cancer
Advances in lung cancer in the Asia-Pacific: Overcoming Resistance in NSCLC
Session summary: Dr Jin-Yuan Shih will teach us about targeted lung cancer screening. From the world leading NTUH research team, we will be able to learn how lung cancer screening proven in two Western population RCTs may apply to the Asian-Pacific population with its diverse ethnicities and different smoking and carcinogen exposures.
We will be updated on lung cancer evolution knowledge gained as a result of modern sequencing techniques including single cell sequencing. Such data will be critical to develop biomarkers that may be combined with radiological lung cancer screening.
Dr Koichi Hagiwara will discuss the lung cancer treatment landscape in Asia: overcoming resistance. This is a hot topic given the large number of people benefitting from these effective therapies but where resistance is very likely to develop. If so, they will require alternative treatment strategies, which we will learn from Dr Hagiwara’s internationally recognized expertise.
These alternative therapies include possible use of immunotherapy, already in common use for advanced lung cancers and now emerging for use in earlier disease. Thus, we look forward to the important expert update by Dr Terufumi Kato.
Chairs: Kwun M Fong (University of Queensland Thoracic Research Centre, The Prince Charles Hospital, Australia)
Sita Andarini (University of Indonesia, Persahabatan Hospital, Jakarta, Indonesia)[Educational Lecture]
Targeted lung cancer screening
Jin-Yuan Shih (National Taiwan University Hospital, Taiwan)[Symposium]
- The evolution of lung cancer
Kwun M Fong (University of Queensland Thoracic Research Centre, The Prince Charles Hospital, Australia) - Lung cancer treatment landscape in Asia: overcoming resistance
Koichi Hagiwara (Jichi Medical University, Japan) - Immunotherapy and beyond for NSCLC
Terufumi Kato (Kanagawa Cancer Center, Japan)
- The evolution of lung cancer
- Assembly Symposium 15: Pulmonary Circulation
Topics of hypoxia induced pulmonary hypertension
Session summary: Hypoxia is a major cause of pulmonary hypertension. The most important pathogenesis of pulmonary hypertension due to lung diseases/hypoxia is "hypoxic pulmonary vasoconstriction (HPV)", and knowing this essential situation will lead to compressively understanding of the pathophysiology of PH Group 3. In addition, it is highly expected that, by thoroughly understanding the pathophysiological progress from HPV to pulmonary hypertension together with the updated knowledge of high-altitude medicine and pulmonary diseases, pulmonologists can gain a wide range of advanced knowledge and insight from pathophysiology to diagnosis and treatment of this illness. I believe, by this symposium, the pulmonologists will achieve the necessities of precision and precise knowledge of pulmonary hypertension.
Chairs: Silvia Ulrich (University Hospital Zurich, Switzerland)
Masayuki Hanaoka (Shinshu University School of Medicine, Japan)[Educational Lecture]
Hypoxic pulmonary vasoconstriction
Yoshiteru Morio (Tokyo National Hospital, Japan)[Symposium]
- Hypoxia and pulmonary hypertension
Silvia Ulrich (University Hospital Zurich, Switzerland) - High Altitude Pulmonary Hypertension (HAPH)
Talant Sooronbaev (Kyrgyz-Swiss High Altitude Medical and Research Center, Kyrgyz Republic) - Experimental and clinical approach for pulmonary hypertension due to lung disease
Masayuki Hanaoka (Shinshu University School of Medicine, Japan)
- Hypoxia and pulmonary hypertension
- Assembly Symposium 16: Asthma
Biologics for the management of asthma
Session summary: Severe asthma encompasses multiple different subgroups or phenotypes with a greater risk of exacerbations and a rapid decline in lung function. Biologics targeting type 2 cytokine (IL-5 and IL4/IL-13) and IgE have been developed to improve its management. Asthma phenotypes, biomarkers, comorbid conditions, and clinical responses could help the optimal choice of therapeutic drugs. In contrast, little therapeutic options are available in non-type 2 or type 2-low asthma. This session offers a golden opportunity to improve our understanding of the pathophysiology of severe asthma and clinical process to determine which class of biologic is appropriate for a given patient with uncontrolled asthma.
Chairs: Kang-Yun Lee (Taipei Medical University, Taiwan)
Jun Miyata (National Defense Medical College, Japan)[Educational Lecture]
Biologics for the management of asthma
Nobuaki Miyahara (Okayama University Academic Field of Health Sciences, Japan)[Symposium]
- Biologics and irritant asthma
James G Martin (McGill University, Canada) - Diverse phenotypes and selection of the biologics in asthma
Hae-Sim Park (Ajou University Medical Center, Republic of Korea) - Predictive and Response Biomarkers for Biologics in Asthma
Norihiro Harada (Juntendo University, Japan)
- Biologics and irritant asthma
